RE:Stats for the upcoming financialsThe results are in for Q4. They reported core business revenues of 29.0 which beat the high end of their guidance range 27.8-28.8. This is good news.
The total net revenues of 32.0 also beat the high end of their guidance range of $29.3-30.5. This is good news.
Their net income per share at 0.10 beat of the analyst estimate range of 0.05-0.09. This is good news.
Vent patients reported were 8,405 up from 8,200. They are capable of more.
They issued a pretty conservative estimate for 2022 Q1 but given that in the first six weeks the hospitals were overtaken by the Omicron wave, I was expecting growth in Q1 at 1/2 pace.